|Company Name||BeiGene, Ltd.|
On September 5, 2019, J Capital Research published a report alleging, among other things, that BeiGene “is faking sales in order to persuade investors that it can develop a successful platform in China” and that “management may also be skimming R&D and capital budgets.”
On this news, BeiGene’s American depositary receipt price fell $19.95 per share, or 14.19%, over the following two trading sessions to close at $120.61 on September 6, 2019, thereby injuring investors.
Submit Your Information
If you suffered a loss on your BeiGene, Ltd. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.
An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.